Renal Denervation by MDT-2211 System in Patients With Uncontrolled Hypertension (HTN-J)
Primary Purpose
Uncontrolled Hypertension
Status
Completed
Phase
Not Applicable
Locations
Japan
Study Type
Interventional
Intervention
MDT-2211 Renal Denervation System
Sponsored by

About this trial
This is an interventional treatment trial for Uncontrolled Hypertension focused on measuring Hypertension, Vascular Diseases, Cardiovascular Diseases, Renal denervation
Eligibility Criteria
Inclusion Criteria:
- Individual is ≥ 20 and ≤ 80 years old at time of randomization.
- Individual is receiving a stable medication regimen including full tolerated doses of 3 or more anti-hypertensive medications of different classes, of which one must be a diuretic (with no changes for a minimum of 6 weeks prior to screening) that is expected to be maintained without changes for at least 6 months.
- Individual has an office systolic blood pressure (SBP) of ≥ 160 mmHg based on an average of 3 blood pressure readings measured at both an initial screening visit and a confirmatory screening visit
- Individual agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study.
Exclusion Criteria highlights:
- Individual has an estimated glomerular filtration rate (eGFR) of < 45 mL/min/1.73 m2
- Individual has an Ambulatory Blood Pressure Monitoring (ABPM) 24 hour average SBP < 135 mmHg
- Individual has type 1 diabetes mellitus
- Individual requires chronic oxygen support or mechanical ventilation (e.g., tracheostomy, CPAP, BiPAP) other than nocturnal respiratory support for sleep apnea.
- Individual has primary pulmonary hypertension.
- Individual is pregnant, nursing or planning to be pregnant.
Sites / Locations
- Hirosaki University School of Medicine & Hospital
- Chiba University Hospital
- Ehime University Hospital
- Kyushu University Hospital
- Kurume University Hospital
- Asahikawa Medical University Hospital
- Sapporo Medical University Hospital
- Higashi Takarazuka Satoh Hospital
- Tsukuba University Hospital
- Shonan Kamakura General Hospital
- Yokohama Tobu Hospital
- Kumamoto University Hospital
- Kyoto University Hospital
- Osaka University Hospital
- Jichi Medical University Hospital
- Mitsui Memorial Hospital
- Tokyo Women's Medical University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Renal denervation
Control Group
Arm Description
Subjects are treated with the renal denervation procedure after randomization and are maintained on baseline anti-hypertensive medications.
Subjects are maintained on baseline anti-hypertensive medications
Outcomes
Primary Outcome Measures
Change in Office Systolic Blood Pressure
Secondary Outcome Measures
Incidence of Major Adverse Events (MAE)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01644604
Brief Title
Renal Denervation by MDT-2211 System in Patients With Uncontrolled Hypertension
Acronym
HTN-J
Official Title
The Clinical Study of Renal Denervation by MDT-2211 System in Patients With Uncontrolled Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
July 2012 (undefined)
Primary Completion Date
April 2015 (Actual)
Study Completion Date
June 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic Vascular
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The objective of this study is to demonstrate that the MDT-2211 renal denervation system is a safe and effective treatment for uncontrolled hypertension subjects despite treatment with 3 or more anti-hypertensive medications of different classes, of which one must be a diuretic, as best available antihypertensive therapy
Detailed Description
The HTN-J study is a multi-center, prospective, unblinded, randomized, controlled study of the safety and effectiveness of renal denervation in subjects with uncontrolled hypertension. Bilateral renal denervation will be performed using the MDT-2211 renal denervation system - a percutaneous system that delivers radiofrequency (RF) energy through the luminal surface of the renal artery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uncontrolled Hypertension
Keywords
Hypertension, Vascular Diseases, Cardiovascular Diseases, Renal denervation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
41 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Renal denervation
Arm Type
Experimental
Arm Description
Subjects are treated with the renal denervation procedure after randomization and are maintained on baseline anti-hypertensive medications.
Arm Title
Control Group
Arm Type
No Intervention
Arm Description
Subjects are maintained on baseline anti-hypertensive medications
Intervention Type
Device
Intervention Name(s)
MDT-2211 Renal Denervation System
Intervention Description
A percutaneous system that delivers radiofrequency (RF) energy through the luminal surface of the renal artery.
Primary Outcome Measure Information:
Title
Change in Office Systolic Blood Pressure
Time Frame
Baseline to 6 months post-randomization
Secondary Outcome Measure Information:
Title
Incidence of Major Adverse Events (MAE)
Time Frame
Baseline through 1 month post-randomization
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Individual is ≥ 20 and ≤ 80 years old at time of randomization.
Individual is receiving a stable medication regimen including full tolerated doses of 3 or more anti-hypertensive medications of different classes, of which one must be a diuretic (with no changes for a minimum of 6 weeks prior to screening) that is expected to be maintained without changes for at least 6 months.
Individual has an office systolic blood pressure (SBP) of ≥ 160 mmHg based on an average of 3 blood pressure readings measured at both an initial screening visit and a confirmatory screening visit
Individual agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study.
Exclusion Criteria highlights:
Individual has an estimated glomerular filtration rate (eGFR) of < 45 mL/min/1.73 m2
Individual has an Ambulatory Blood Pressure Monitoring (ABPM) 24 hour average SBP < 135 mmHg
Individual has type 1 diabetes mellitus
Individual requires chronic oxygen support or mechanical ventilation (e.g., tracheostomy, CPAP, BiPAP) other than nocturnal respiratory support for sleep apnea.
Individual has primary pulmonary hypertension.
Individual is pregnant, nursing or planning to be pregnant.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kazuyuki Shimada, MD
Organizational Affiliation
New Oyama Municipal Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hirosaki University School of Medicine & Hospital
City
Hirosaki-shi
State/Province
Aomori
ZIP/Postal Code
036-8563
Country
Japan
Facility Name
Chiba University Hospital
City
Chiba-shi
State/Province
Chiba
ZIP/Postal Code
260-8677
Country
Japan
Facility Name
Ehime University Hospital
City
Toon
State/Province
Ehime
ZIP/Postal Code
791-0295
Country
Japan
Facility Name
Kyushu University Hospital
City
Fukuoka-shi
State/Province
Fukuoka
ZIP/Postal Code
812-8582
Country
Japan
Facility Name
Kurume University Hospital
City
Kurume-shi
State/Province
Fukuoka
ZIP/Postal Code
830-0011
Country
Japan
Facility Name
Asahikawa Medical University Hospital
City
Asahikawa
State/Province
Hokkaido
ZIP/Postal Code
078-8510
Country
Japan
Facility Name
Sapporo Medical University Hospital
City
Sapporo-shi
State/Province
Hokkaido
ZIP/Postal Code
060-8543
Country
Japan
Facility Name
Higashi Takarazuka Satoh Hospital
City
Takarazuka
State/Province
Hyogo
ZIP/Postal Code
665-0873
Country
Japan
Facility Name
Tsukuba University Hospital
City
Tsukuba
State/Province
Ibaraki
ZIP/Postal Code
305-8576
Country
Japan
Facility Name
Shonan Kamakura General Hospital
City
Kamakura
State/Province
Kanagawa
ZIP/Postal Code
247-8533
Country
Japan
Facility Name
Yokohama Tobu Hospital
City
Yokohama
State/Province
Kanagawa
ZIP/Postal Code
230-0012
Country
Japan
Facility Name
Kumamoto University Hospital
City
Kumamoto-shi
State/Province
Kumamoto
ZIP/Postal Code
860-8556
Country
Japan
Facility Name
Kyoto University Hospital
City
Sakyo-ku
State/Province
Kyoto
ZIP/Postal Code
606-8507
Country
Japan
Facility Name
Osaka University Hospital
City
Suita-shi
State/Province
Osaka
ZIP/Postal Code
565-0871
Country
Japan
Facility Name
Jichi Medical University Hospital
City
Shimotsuke
State/Province
Tochigi
ZIP/Postal Code
329-0498
Country
Japan
Facility Name
Mitsui Memorial Hospital
City
Chiyoda-ku
State/Province
Tokyo
ZIP/Postal Code
101-8643
Country
Japan
Facility Name
Tokyo Women's Medical University Hospital
City
Shinjuku-ku
State/Province
Tokyo
ZIP/Postal Code
162-8666
Country
Japan
12. IPD Sharing Statement
Citations:
PubMed Identifier
26558819
Citation
Kario K, Bhatt DL, Brar S, Cohen SA, Fahy M, Bakris GL. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension. 2015 Dec;66(6):1130-7. doi: 10.1161/HYPERTENSIONAHA.115.06260. Epub 2015 Oct 5.
Results Reference
derived
PubMed Identifier
25912693
Citation
Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, Haskin R, Negoita M, Shimada K; SYMPLICITY HTN-Japan Investigators. SYMPLICITY HTN-Japan - First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients -. Circ J. 2015;79(6):1222-9. doi: 10.1253/circj.CJ-15-0150. Epub 2015 Apr 24.
Results Reference
derived
Learn more about this trial
Renal Denervation by MDT-2211 System in Patients With Uncontrolled Hypertension
We'll reach out to this number within 24 hrs